6533b86cfe1ef96bd12c8383
RESEARCH PRODUCT
Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy
Judit OvádiF OroszAttila LehotzkyVirginia MerinoN TőkésiMarival BermejoGabor G. KovacsI. González-alvarezPierre Lausubject
MaleDrugmedicine.medical_specialtyGeneral Mathematicsmedia_common.quotation_subjectCancer therapyGeneral Physics and AstronomyAntineoplastic AgentsNerve Tissue Proteinsanti-mitotic drugReviewVinblastineMicrotubulesModels Biologicalanti-mitotic proteinTubulinCell Line TumorNeoplasmsKAR-2Biomarkers TumormedicineAnimalsHumanscancerRats WistarIntensive care medicinemedia_commonTPPP/p25Dose-Response Relationship Drugbusiness.industryGeneral EngineeringCancermedicine.diseaseRatsDrug marketbioavailabilitybusinessdescription
Cancer continues to be one of the major health and socio-economic problems worldwide, despite considerable efforts to improve its early diagnosis and treatment. The identification of new constituents as biomarkers for early diagnosis of neoplastic cells and the discovery of new type of drugs with their mechanistic actions are crucial to improve cancer therapy. New drugs have entered the market, thanks to industrial and legislative efforts ensuring continuity of pharmaceutical development. New targets have been identified, but cancer therapy and the anti-cancer drug market still partly depend on anti-mitotic agents. The objective of this paper is to show the effects of KAR-2, a potent anti-mitotic compound, and TPPP/p25, a new unstructured protein, on the structural and functional characteristics of the microtubule system. Understanding the actions of these two potential effectors on the microtubule system could be the clue for early diagnosis and improvement of cancer therapy.
year | journal | country | edition | language |
---|---|---|---|---|
2008-07-21 | Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences |